Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core.
Yu, T., Tagat, J.R., Kerekes, A.D., Doll, R.J., Zhang, Y., Xiao, Y., Esposite, S., Belanger, D.B., Curran, P.J., Mandal, A.K., Siddiqui, M.A., Shih, N.Y., Basso, A.D., Liu, M., Gray, K., Tevar, S., Jones, J., Lee, S., Liang, L., Ponery, S., Smith, E.B., Hruza, A., Voigt, J., Ramanathan, L., Prosise, W., Hu, M.(2010) ACS Med Chem Lett 1: 214-218
- PubMed: 24900197 
- DOI: https://doi.org/10.1021/ml100063w
- Primary Citation of Related Structures:  
3MYG - PubMed Abstract: 
The imidazo-[1,2-a]-pyrazine (1) is a dual inhibitor of Aurora kinases A and B with modest cell potency (IC50 = 250 nM) and low solubility (5 μM). Lead optimization guided by the binding mode led to the acyclic amino alcohol 12k (SCH 1473759), which is a picomolar inhibitor of Aurora kinases (TdF K d Aur A = 0.02 nM and Aur B = 0.03 nM) with improved cell potency (phos-HH3 inhibition IC50 = 25 nM) and intrinsic aqueous solubility (11.4 mM). It also demonstrated efficacy and target engagement in human tumor xenograft mouse models.
Organizational Affiliation: 
Departments of Chemical Research.